Merck quarterly profit buoyed by Keytruda demand as COVID-19 hammers sales

This post was originally published on this site

(Reuters) – Merck & Co Inc (MRK.N) on Friday posted a higher-than-expected quarterly profit and raised its full-year earnings forecast on resilient demand for its blockbuster cancer therapy Keytruda during the COVID-19 pandemic, sending its shares up 3%.

Click here to read full article